Kevin Winthrop, MD, MPH
Kevin L. Winthrop, Professor of Public Health, Infectious Diseases, and Ophthalmology at Oregon Health and Science University, is a former staff infectious disease epidemiologist from the U.S. Centers for Disease Control and Prevention’s Division of Tuberculosis Elimination. He has co-authored over 300 publications, many detailing the epidemiologic and clinical aspects of nontuberculous mycobacterial diseases (NTM), tuberculosis, and other infections associated with rheumatic diseases and biologic immunosuppressive therapies. Clinically, he provides regional consultations for mycobacterial diseases and other chronic chest infections and serves as the medical consultant to the Oregon Public Health Division’s TB control program. His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials. He has served as a primary or senior investigator in many of these clinical and epidemiologic studies, and frequently collaborates with the Pulmonary Department on studies related to bronchiectasis. He founded the NTM Research Consortium and associated Clinical Trials Network which facilitate collaborative, multi-site grants and clinical trials among patients with NTM. He is a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.
Financial relationships
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:InsmedTopic:NTMDate added:Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Research Funding (if you were the principal or named investigator)Ineligible company:InsmedTopic:NTM researchDate added:Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:RedHill BiopharmaTopic:NTMDate added:Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Research Funding (if you were the principal or named investigator)Ineligible company:RedHill BiopharmaTopic:NTM researchDate added:Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:SperoTopic:NTMDate added:Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AN2 TherapeuticsTopic:NTMDate added:02/07/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Research Funding (if you were the principal or named investigator)Ineligible company:AN2 TherapeuticsTopic:NTM researchDate added:02/07/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:ParatekTopic:NTMDate added:02/07/2022Date updated:04/29/2024
-
Attribution:SelfType of financial relationship:Research Funding (if you were the principal or named investigator)Ineligible company:ParatekTopic:NTM researchDate added:02/07/2022Date updated:04/29/2024